Fresh from re­brand, Spyre Ther­a­peu­tics rais­es $180M as it steers TLA1 pro­gram to clin­ic

Spyre Ther­a­peu­tics is pulling in $180 mil­lion in a pri­vate place­ment just a cou­ple of weeks af­ter it re­brand­ed from Ae­glea Bio­Ther­a­peu­tics.

Spyre is sell­ing 6 mil­lion shares of its com­mon stock at $15 per share and 150,000 shares of its Se­ries B pre­ferred stock at $600 per share in a pri­vate place­ment. It’s ex­pect­ed to close around Dec. 11.

The pri­vate place­ment will ex­tend the biotech’s cash run­way in­to the sec­ond half of 2026 and sup­port de­vel­op­ment of its pipeline for gen­er­al cor­po­rate pur­pos­es and work­ing cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER